Kristen rat sarcoma viral oncogene (KRAS), epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are the most commonly altered oncogenes by acting as tumour genomic drivers.4 More recently, the identification of activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements as predictive biomarkers for treatment of NSCLC led to further personalization of therapy with EGFR tyrosine kinase inhibitors (EGFR‐TKIs) and ALK inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.